Currently, there are 31.79M common shares owned by the public and among those 29.70M shares have been available to trade.
The company’s stock has a 5-day price change of -17.39% and -61.49% over the past three months. CLDI shares are trading -85.53% year to date (YTD), with the 12-month market performance down to -75.22% lower. It has a 12-month low price of $0.28 and touched a high of $3.89 over the same period. CLDI has an average intraday trading volume of 390.17K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -17.27%, -30.15%, and -71.90% respectively.
Institutional ownership of Calidi Biotherapeutics Inc (AMEX: CLDI) shares accounts for 17.13% of the company’s 31.79M shares outstanding.
It has a market capitalization of $9.06M and a beta (3y monthly) value of 1.06. The earnings-per-share (ttm) stands at -$1.84. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.11% over the week and 3.80% over the month.
Analysts forecast that Calidi Biotherapeutics Inc (CLDI) will achieve an EPS of -0.11 for the current quarter, -0.1 for the next quarter and -0.32 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.11 while analysts give the company a high EPS estimate of -0.11. Earnings per share for the fiscal year are expected to increase by 84.85%, and 28.89% over the next financial year.
Looking at the support for the CLDI, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on November 22, 2023, with the firm’s price target at $11. Robert W. Baird coverage for the Calidi Biotherapeutics Inc (CLDI) stock in a research note released on October 09, 2023 offered a Outperform rating with a price target of $9.
